Advanced Filters
noise
Found 842 clinical trials
G Go to Site Finder https://www.alz-net.org/Find-a-Site

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments …

18 years of age All Phase N/A
T Tengfei Guo, Ph.D.

Greater-Bay-Area Healthy Aging Brain Study (GHABS)

The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows: The prevalence and characteristics of AD in South China's aging population Identify novel biomarkers and neuroimaging techniques for early …

55 - 90 years of age All Phase N/A
D Dolly Reyes-Dumeyer

Late Onset Alzheimer's Disease

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

55 years of age All Phase N/A

A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab

The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.

18 years of age All Phase N/A

A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease

The primary purpose of this study is to evaluate safety of lecanemab in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in participants treated with lecanemab.

18 years of age All Phase N/A

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.

50 - 90 years of age All Phase N/A
K Karine Fauria, PhD

Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants

Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression. Cross-sectional and single arm study performed on a subgroup of individuals recruited in the ALFA project. Study without therapeutic interest for the research participants (440 participants of the ALFA project who …

45 - 75 years of age All Phase N/A

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease

The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments …

60 years of age All Phase N/A
C Craig Ritchie, Professor, MD, PhD

IONA Longitudinal Cohort Study

Understanding more about how diseases that cause dementia develop is critical as the number of people living with, or affected by, dementia in Scotland continues to grow. The IONA Longitudinal Cohort Study (LCS) has been set up to gather information about people's cognitive health (their memory and thinking abilities), their …

50 - 120 years of age All Phase N/A
Y Yongqin Xiong, MD

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

This single-center prospective cohort study will enroll 750 participants (250 cognitively Normal (CN) individuals, 250 with mild cognitive impairment (MCI), and 250 with Alzheimer's disease (AD)). At baseline and at annual follow-ups, participants will undergo 3 Tesla (3 T) and 7 Tesla (7 T) multimodal magnetic resonance imaging (MRI) scans, …

55 - 90 years of age All Phase N/A

Simplify language using AI